According to a recent industry analysis, the Intravenous Immunoglobulin Market size was valued at USD 14.02 billion in 2024 and is forecast to reach USD 25.39 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.72% over the 2025–2032 period. A surge in immunodeficiency disease diagnoses, expanded plasma collection efforts, and greater adoption of IVIG therapies across hospitals and specialty clinics are key contributors to this robust growth trajectory.
Growth Drivers Fueling the Intravenous Immunoglobulin Market
The rising global burden of primary immunodeficiency disorders (PIDs) continues to be a primary growth driver for the IVIG market. With immunodeficiency diseases accounting for 20% of market revenue in 2024, demand is fueled by increased diagnosis rates and improved therapeutic outcomes using IVIG therapy. IVIG reduces infection recurrence and improves survival in PID patients, especially as many cases remain undiagnosed.
Get a Free Sample Report of Intravenous Immunoglobulin Market@ https://www.snsinsider.com/sample-request/7356
Innovative developments are supporting this momentum. For instance, Biotest’s Yimmugo, approved in June 2024, offers a high-purity formulation designed for substitution therapy in PIDs. Furthermore, government initiatives—such as the opening of 20 new plasma collection centers by Grifols—have improved plasma supply reliability, ensuring a steady stream of raw material for IVIG production.
The growing incidence of Kawasaki disease, particularly in children, is another powerful market stimulant. It remains the leading cause of acquired heart disease among children globally, and IVIG remains the standard treatment. The Asia-Pacific region, with its rising Kawasaki disease burden and strengthened diagnosis protocols, is a key growth contributor. Notably, China’s NMPA approval of a domestic IVIG product for Kawasaki treatment in March 2025 demonstrates regulatory and industrial alignment toward broader accessibility.
Application Insights: Immunodeficiency and Kawasaki Disease Drive Demand
In 2024, immunodeficiency diseases led the IVIG application segment, fueled by greater awareness, early diagnosis, and enhanced IVIG efficacy. The increasing drive to develop novel IVIG delivery formats, such as subcutaneous and prefilled syringes, adds convenience and therapeutic personalization, further expanding its clinical appeal.
Meanwhile, Kawasaki disease applications are projected to grow the fastest over the forecast period. This expansion is supported by heightened pediatric screening programs and increased national investment in IVIG research and local production—highlighting the disease’s rising profile as a critical pediatric concern.
Distribution Channel Analysis: Hospitals Lead While Specialty Clinics Surge
Hospitals commanded a 56% market share in 2024, underscoring their role in administering complex IVIG infusions. With chronic and neurological conditions such as CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) requiring meticulous monitoring, hospitals remain the core treatment setting. Data from the U.S. Department of Health and Human Services confirms a steady rise in hospital-based IVIG therapy, propelled by reimbursement support and early access to new formulations.
However, specialty pharmacies and clinics are emerging as the fastest-growing segment. Their patient-centric care, flexible appointment scheduling, and seamless integration with home-infusion programs are reshaping the IVIG delivery landscape. Backed by the CMS expansion of funding for home-based IVIG in 2024, specialty providers are becoming increasingly viable for patients with chronic autoimmune or neuromuscular conditions.
Recent strategic moves underscore this trend. For example, Takeda Pharmaceuticals’ partnership with specialty clinics in April 2025, and Ridgemont Equity Partners’ acquisition of American Outcomes Management in February 2024, illustrate the growing role of specialty care networks in broadening access to IVIG therapies.
Regional Insights: North America Dominates, Asia-Pacific Accelerates
In 2024, North America held a commanding 45% share of the global IVIG market. The U.S. intravenous immunoglobulin market alone was valued at USD 4.98 billion, projected to reach USD 8.95 billion by 2032. The region’s well-established plasma collection infrastructure, ongoing product innovations, and supportive insurance frameworks drive this dominance. Expansion of plasma donation networks, such as Grifols’ initiatives, continues to align with rising therapy demand.
Asia-Pacific is forecasted to be the fastest-growing regional market, driven by increased healthcare expenditure, enhanced plasma collection programs, and higher rates of Kawasaki disease. National regulatory bodies like China’s NMPA are actively supporting local IVIG manufacturing, ensuring more accessible and affordable treatment options.
Europe remains a strong contributor with robust regulatory support for plasma-derived therapies. Notable regulatory progress includes the UK approval of Biotest’s Yimmugo in September 2023. Meanwhile, emerging regions in Latin America, the Middle East, and Africa (LAMEA) are gradually expanding their IVIG markets due to improving infrastructure and growing awareness of autoimmune and immunodeficiency conditions.
Need Any Customization Research on Intravenous Immunoglobulin Market, Enquire Now@ https://www.snsinsider.com/enquiry/7356
Competitive Landscape: Key Players and Innovations
Key players in the intravenous immunoglobulin market include:
CSL
Biotest AG
Kedrion
BDI Pharma Inc.
Baxter
Octapharma AG
LFB
China Biologics Products Inc.
Shanghai RAAS Blood Products
Shire
Grifols SA
These companies are focusing on product innovation, strategic partnerships, and expansion of plasma collection to meet surging demand. For instance, CSL’s January 2024 launch of a prefilled Hizentra syringe offers enhanced convenience for patients with CIDP and primary immunodeficiency (PI). Similarly, FDA’s approval of GAMMAGARD LIQUID for treating neuromuscular impairment in adults with CIDP in January 2024 signals ongoing clinical development in the IVIG space.
Conclusion
The intravenous immunoglobulin market is experiencing rapid expansion, propelled by increasing prevalence of immune disorders, breakthroughs in therapy delivery, and growing adoption of patient-centric models. As more nations strengthen plasma collection and regulatory approval pathways, the IVIG industry is well-positioned for robust and sustained growth.
For healthcare providers, pharmaceutical companies, and policymakers, this market represents a crucial intersection of innovation, unmet medical need, and expanding global access—ushering in a new era for immunoglobulin therapy.
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
